A Multicenter International Survey of Renal Supportive Therapy During ECMO: The Kidney Intervention During Extracorporeal Membrane Oxygenation (KIDMO) Group

Geoffrey M. Fleming¹, David J. Askenazi², Brian C. Bridges¹, David S. Cooper³, Mathew L. Paden⁴, David T. Selewski⁵, and Michael Zappitelli⁶

¹Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee
²Department of Pediatrics, University of Alabama Birmingham, Birmingham, Alabama
³Department of Pediatrics, The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio
⁴Department of Pediatrics, Emory University, Atlanta, Georgia
⁵Department of Pediatrics and Communicable Diseases, University of Michigan School of Medicine, Ann Arbor, Michigan
⁶Department of Pediatrics, McGill University Health Centre, Montreal, Canada

Abstract

Acute kidney injury and fluid overload (FO) are associated with increased mortality in critically ill patients, including the subset supported with extracorporeal membrane oxygenation (ECMO). The indication for and method of application of renal support therapy (RST) during ECMO is largely unknown beyond single-center experiences. The current study uses a survey design to document practice variation regarding RST, including indication, method of interface with the ECMO circuit, and prescribing practices. Sixty-five international ECMO centers (31%) responded to an online electronic survey regarding RST during ECMO. Nearly a quarter of centers (23%) reported using no RST during ECMO. Among those using the therapy, the predominant mode of therapy applied was convection and included slow continuous ultrafiltration and continuous veno-venous hemofiltration. The predominant indication for RST was the treatment (43%) or prevention (16%) of FO. Nephrology rather than critical care medicine is reported as the prescribing service in a majority of centers with a significant difference between US centers and non-US centers. The results of this study identify a wide variation in practice regarding RST during ECMO that will offer multiple important avenues for further research by this group and others regarding the interface of RST and ECMO.

Correspondence: Geoffrey Fleming, MD — Vanderbilt University School of Medicine, 5112 DOT, 2200 Children’s Way, Nashville, TN, 37232. geoffrey.fleming@vanderbilt.edu.
INTRODUCTION

Acute kidney injury (AKI) and the need for renal supportive therapies (RST) are both associated with significant negative effects on outcomes in critically ill adults and children. Additionally, cumulative fluid overload (FO) during critical illness is associated with mortality and may represent a surrogate of kidney injury. Among critically ill patients on extracorporeal membrane oxygenation (ECMO) support, AKI and FO are associated with worse outcome. Despite this known association, remarkably little is known about patients on ECMO receiving concomitant RST for AKI or FO. The majority of published data are from single-center experiences that may not be extrapolated accurately to the larger ECMO population. Of note are the fundamental questions surrounding RST such as the mode employed, the indication for RST, and the method of interfacing with the ECMO circuit.

During ECMO, continuous RST is most often accomplished by including an in-line hemodialysis filter as a shunt off the main ECMO circuit or connecting a conventional continuous RST machine to the circuit. Both convection and diffusion have been studied as modes of RST in the critically ill population, with little clear advantage of one therapy over the other demonstrated to date, despite superior convective “middle molecule” clearance. In the ECMO population, the majority of reported RST has used convective clearance. Little is known about the indication for RST employed by centers during ECMO beyond single-center experiences.

The Extracorporeal Life Support Organization (ELSO) Registry contains voluntarily reported data on demographics, laboratory and diagnostic information, and clinical course for neonates, children, and adults treated with ECMO around the world. The ELSO data forms do not include data regarding the indication for RST, but simply if it was employed. Because of the lack of data available on RST during ECMO, management is based on local and regional expert opinion, most likely leading to significant variability in practice. This hinders the ability to evaluate the effect of RST on ECMO and other outcomes as well as to evaluate the efficacy of AKI and FO as indications for RST.

The Kidney Intervention During Extracorporeal Membrane Oxygenation study group has been formed to systematically answer questions regarding the use of RST during ECMO. An initial objective of the study group was to understand current RST practice among the international ECMO community. This is a necessary first step toward eventually suggesting a systematic approach toward caring for these patients and ultimately improving outcomes of children receiving RST on ECMO. The goal of this study was to describe RST practice variation during ECMO, specifically regarding the mode employed, indication for RST, and the method of interfacing with the circuit.

METHODS

Study Design and Recruitment

We performed a cross-sectional survey of center practices with regard to RST during ECMO. Individuals subscribing to the ECLSNet ListServe (eclsnet@rufus.origenbio.com),
were eligible. ECLSNet ListServe is an electronic forum for information sharing among participating centers. Membership to ECLSNet is voluntary and limited to health care professionals who are members of, or associated with, an institution that is a member of the ELSO. The site is hosted outside of the ELSO administration. An e-mail recruiting participants was posted on the ECLSNet ListServe on March 20, 2010 and included a link to the survey as well as the closure date of the study as April 15, 2010. The e-mail requested only one response per institution to be completed by the program coordinator or medical director. To enhance response rate, a subsequent reminder e-mail was sent out April 1, 2010. No incentive was provided for participation. The questionnaire was anonymous, with no personal data collected except for country location and role of the respondent in ECMO care. Institutional Review Board approval for the study was obtained at the host institution (Vanderbilt University School of Medicine, Nashville, TN) before implementation.

Survey Design

A 29 question web-based survey was created using REDCap electronic data capture tools hosted at Vanderbilt University School of Medicine. The survey was created using a modified Delphi technique with the multiple members of the research group as the surveyed experts. Survey questions were designed by one author (G.M.F.) and distributed for comments and modification within the study group. After several similar revisions, the final questionnaire was approved and piloted by all authors. The questionnaire was not tested for reliability or generalizability, but content validity is derived from the method of creation using the modified Delphi method among experts in the field. The survey was designed using branching logic where questions presented are dependent upon answers to the previous question, allowing for an expandable survey dependent upon the responses.

Survey Description

The full survey is available in Appendix A and takes approximately 15 minutes to complete. The survey included center-specific information such as the respondent’s role and the location by continent. Extracorporeal membrane oxygenation related data included age group and indication for ECMO among patients cared for at the institution. Questions specific to RST requested the mode employed, the indication for RST, the prescribing physician group for RST, the method of interface with the ECMO circuit, and equipment used. For questions regarding mode (interface with the circuit and indication for RST), respondents were asked two separate questions, one regarding the range of modes employed and one regarding the mode employed most often.

Statistical Analysis

All variables were categorical and expressed as frequencies and percentages. Comparisons among groups were performed using the chi-square test. Analysis was performed using STATA SE statistical software package (College Station, TX).
RESULTS

Description of ECMO Centers and ECMO Indications

A total of 65 centers subscribing to ECLSnet responded. ECLSnet was unable to provide us with what proportion of the 210 ELSO centers (according to the ELSO website: http://www.elso.med.umich.edu/) currently subscribe to ECLSnet. Therefore, the response rate was estimated as at least 31% (65) of 210 international ELSO centers of which 52 (80%) were US sites (38.2% of published US ELSO centers), 3 (4.6%) were Canadian (30% of published Canadian ELSO centers), 7 (10.8%) were European (13% of published European ELSO centers), and 3 (4.6%) were from Australia or New Zealand (33% of published Australia/New Zealand centers). Of the 65 respondents, 51 (78.5%) were program coordinators, 6 (9.2%) were program directors, and 8 (12.3%) were categorized as “other”. The majority of centers cared for non-adult patients on ECMO; 61 (94%) centers reported caring for neonatal or pediatric patients, 26 (40%) cared for adults on ECMO of which 2 (3%) centers cared exclusively for adults. Thirty (46%) centers reported that their patients had an equal distribution of cardiac and respiratory indications for ECMO, 18 (27.7%) reported the majority indication was cardiac support only, 16 (24.6%) reported the majority indication was respiratory support only, and 1 center did not provide data.

RST Indications and Prescription

Fifteen centers (23%) reported not using any RST during ECMO, and these respondents did not progress through the remainder of the survey as a result of branching logic design. The most frequently reported indications for RST were the treatment of FO (43%), prevention of FO (16%), AKI (35%), electrolyte disturbances (4%), and “other” (2%). As shown in Figure 1, there was a tendency for non-US sites to perform RST more frequently for AKI (46.2% vs. 30.2%), but the difference was not statistically significant (p = 0.5). The predominant indication for RST differed among groups based on the center’s predominant ECMO indication; however, these differences did not reach statistical significance with p > 0.05. Among centers reporting predominant cardiac support, AKI was the most frequent indication for RST, whereas the indication of FO was most frequently reported among centers providing both respiratory and cardiac support (Figure 2).

Of the centers that reported using RST during ECMO, 63% responded that nephrology authored the RST prescription, 33% of centers reported critical care medicine services wrote the prescription, and 4% described a dual authorship. Centers in the US were much more likely than non-US centers (83.3 vs. 11.1%, p < 0.001) to report that nephrology authored RST prescriptions. Only 74% of centers reported nephrology routinely following patients on RST during ECMO, with US centers more commonly involving the nephrology service (US vs. non-US nephrology consultations were 94.4% and 5.6% respectively, p < 0.001). In centers where the critical care medicine service authored prescriptions, 27.8% also reported nephrology consultation.

RST Modality

The predominant RST modality reported was convection and included continuous venovenous hemofiltration (CVVH) (43.4%) and slow continuous ultrafiltration (SCUF) (18%).
The modality used was affected by method of interface with the ECMO circuit with SCUF predominating in the in-line filter group (47%) and CVVH in the machine interface group (47%) (Figure 3). Of note, 35% of centers using an in-line hemodiafilter reported using CVVH as the primary modality. Among the centers using in-line filters 83% reported using standard intravenous (IV) pumps for ultrafiltrate control, with 17% using scales.

**RST Interface**

Fourteen (21.5%) centers exclusively used an in-line hemodiafilter and 33 (50.8%) centers exclusively used a continuous RRT (CRRT) machine connected to the circuit. For the 17 (26%) centers that routinely included a hemodiafilter in the circuit construction, 53% used a polysulfone membrane. Of the 36 centers that used a machine during ECMO, 30 (83%) used a Gambro (Lakewood, CO) product including the Prisma (25%) and PrismaFlex (58%). These machines were connected to the venous limb only of the ECMO circuit in 42% of centers, to the arterial limb (pre-oxygenator) in 33% of cases, with the remainder representing a blend of connection sites dependent upon ECMO pump type.

**DISCUSSION**

These survey data summarize several aspects of practice variations that exist in RST use during ECMO, which were previously unreported in the literature. First, nearly one quarter of responding centers report using no RST during ECLS, which is interesting given that AKI incidence may be as high as 72% in certain subgroups and underestimated by current definitions employed in the ELSO registry. No data were collected during this study to provide further insight into this finding. The authors postulate this may represent multiple factors including lack of recognition of AKI, belief that RST contributes to AKI and is consciously avoided, or lack of support for RST in the intensive care unit. The survey questions used the term “Acute Renal Failure” regarding indications for RST, but did not provide any specific definition that may have led to under-reporting of AKI among respondents. A currently implemented change in the ELSO data registry is the collection of serum-creatinine data on all patients in the registry. This will allow identification of AKI by newer consensus definitions in all patients, thus enabling a comparison of outcomes among those with AKI but who do not receive RST.

For centers using RST during ECMO, use of an in-line hemodiafilter and IV pumps to monitor and manage ultrafiltration rates was common. Although no current published data exist regarding the accuracy of in-line CRRT machines during ECMO, published data show that inaccuracies with IV pumps may be as high as 40% when used to control CVVH. Slow continuous ultrafiltration remains a frequent modality for RST during ECMO; however, this therapy modality carries the risk of significant monitoring error and is at risk for producing electrolyte derangements and rapid volume shifts in the ECMO population less than 10 kg. The incidence and prevalence of these complications will be elucidated by the newer data collection tool through the registry that specifically examines patient complications during RST on ECMO.

Indication for RST varied by center location as well as indication for ECMO. It appears that AKI is a problem more predominantly appreciated in the cardiac support group, likely
reflecting the documented incidence of renal injury associated with cardiopulmonary bypass. Fluid overload is a more prevalent indication for RST in the respiratory support group, perhaps driven by the group’s desire to control FO and hasten recovery from acute respiratory distress syndrome. Of note, 20% of centers performing RST during ECMO reported “preventing FO” as the indication for RST. This suggests that despite the lack of class Ia evidence that early initiation of RST may prevent complications, there is a prevalent belief that early prevention of FO may prevent significant pulmonary or other complications. This may be driven by several recent studies demonstrating that FO in critically ill patients and in those receiving CRRT is associated with higher mortality even when controlling for severity of illness.\textsuperscript{11–16,20,29,31,33} Future studies will need to elucidate the definition of FO in the ECMO population and its link to AKI.

Limitations of this study are related to the nature of an anonymous survey posted in a listserv environment. The e-mail was written in English with no translation available, and posted on a listserv with English-language predominance. Additionally, individual centers were not targeted as part of the survey, hence response rates were lower than might have been achieved with targeted recruitment. Finally, survey questions may produce biased results if respondent interpretation differed from the authored intent or if lack of definitions for terms such as “Acute Renal Failure” or “Fluid Overload” led to underreporting because of lack of recognition among respondents.

Despite these limitations, clear themes emerged from this work. First, nearly one quarter of centers report not using any RST during ECMO despite a significant incidence of AKI during ECMO. Second, there is significant practice variation in how clinicians prescribe and perform RST during ECMO with additional differences in the perceived indications for therapy between US and non-US centers. These variations are important to demonstrate before devoting significant effort and resources toward standardizing practice and more detailed evaluation/research. However, the variety in practice is not surprising given the scant amount of data available to guide best practice. No consensus exists regarding optimal mode or dose of RST in the critically ill population. Fluid overload has become a more widely recognized indication for RST in recent years whereas consensus definitions of AKI have increased recognition of organ dysfunction. Yet significant barriers likely still exist among practitioners with regard to the application of RST to all patients with AKI and FO because of under-recognition or disbelief of the data. Another important learning point is that to achieve the eventual goals of RST standardization and performing clinical trials to compare different modes of RST for AKI treatment during ECMO, it will be necessary to arrive at a consensus, ideally at an international level, for knowledge translation and application to be successful. The level of practice variation we have documented greatly supports the recent addition of a renal module to the ELSO registry data forms, which will include data regarding AKI, FO, and details on RST modality used. This information will enable us to better understand the effect of RST and of renal dysfunction during ECMO on outcomes, thereby allowing for goal-directed and targeted future studies to standardize practice and improve ECMO outcomes.
### APPENDIX Renal Replacement Therapy during ECLS

We are interested in you for taking the time to respond to this survey. The purpose of this survey is to gather data from ECLS centers regarding Renal Replacement Therapy (RRT) during ECLS. Most importantly, we will use these data to develop a comprehensive guideline on RRT during ECLS. As stated above, we will only use one survey per institution. Thank you again for your participation in this project. The WFOT eGFR Study Group.

**Respondent’s role:**
- [ ] Program Director
- [ ] Program Coordinator
- [ ] Other

**Where is your institution?**
- United States
- Canada
- Europe
- South America
- Asia
- Other

**Which Country?**
- [ ] United States
- [ ] Canada
- [ ] Europe
- [ ] South America
- [ ] Asia
- [ ] Other

**Age group on ECLS at your institution:**
- [ ] Neonates (0-29 days)
- [ ] Pediatric (1 month-18 years)
- [ ] Adult (18-110 years)

**The MAJORITY of patients receive ECLS support for which indication?**
- [ ] Cardiac (e.g., congenital heart disease, Cardiac surgery)
- [ ] Contraction asplenia etc.
- [ ] Respiratory Failure (ARDS, Lung transplantation etc.)
- [ ] Other (please list below)
- [ ] Other
- [ ] Don’t know

**Do you routinely include a hemofilter (hemocentrifuge) in the combination of your ECLS circuit?**
- [ ] Always
- [ ] Never
- [ ] Other
- [ ] Don’t know

**Which hemofilter (hemocentrifuge): TYPE do you include in line? (Check all that apply)**
- [ ] ANB-6
- [ ] Biokarb
- [ ] Other
- [ ] Don’t know

**How do you control/determine dialysate fluid or ultrafiltrate volume when using an in-line filter?**
- [ ] Dialysate (in liters)
- [ ] Other
- [ ] Don’t know

**Describe your fluid control strategy.**

**Which mode of therapy do you employ using an in-line filter? (Check all that apply)**
- [ ] SCUF
- [ ] CVVH
- [ ] CVVHD
- [ ] CVVHDF

**Which mode of therapy do you employ the MAJORITY of the time when using an in-line filter? (Choose only one)**
- [ ] SCUF
- [ ] CVVH
- [ ] CVVHD
- [ ] CVVHDF

**Do you change your in-line hemofilter (hemocentrifuge) by protocol? (i.e., after ______ hours)?**
- [ ] No
- [ ] Yes

**Do you ever connect a machine to the circuit to perform CPR/OLED (i.e., during)?**
- [ ] Yes
- [ ] No

**Where do you connect the machine to the ECLS circuit?**
- [ ] Vascular Line
- [ ] Arterial Line (post-regeneratior)
- [ ] Arterial Line (dial filter)
- [ ] Other

**Which machine do you use? (Check all that apply)**
- [ ] ARTMA
- [ ] Fresenius VAS
dad
- [ ] Haemonetics
- [ ] More
- [ ] Other

**Which machine?**

**What hemofilter do you use with the machine? (Check all that apply)**
- [ ] ANB-6
- [ ] Biokarb
- [ ] Other
- [ ] Don’t know

**Which filter do you use?**

**Which mode of therapy do you employ using the machine? (Check all that apply)**
- [ ] SCUF
- [ ] CVVH
- [ ] CVVHD
- [ ] CVVHDF

**Which mode of therapy do you employ the MAJORITY of the time using the machine? (Choose only one)**
- [ ] SCUF
- [ ] CVVH
- [ ] CVVHD
- [ ] CVVHDF
- [ ] Other

**Do you change your machine hemofilter (hemocentrifuge) by protocol? (i.e., after ______ hours)?**
- [ ] No
- [ ] Yes

**Who writes the prescription for CPR/OLED (i.e., during)?**
- [ ] Nephrology
- [ ] Critical Care Medicine
- [ ] Other
References


ASAIO J. Author manuscript; available in PMC 2017 June 27.


Figure 1.
Indications for renal support therapy by location.
Black bars, US center; white bars, non-US center; FO, fluid overload; AKI, acute kidney injury.
Figure 2.
Indications for renal support therapy by predominant indication for ECMO.
Black bars, cardiac; white bars, respiratory; gray bars, cardiac + respiratory; FO, fluid overload; AKI, acute kidney injury; ECMO, extracorporeal membrane oxygenation.
Figure 3.
Mode of RST by interface with the ECMO circuit.
Black bars, in-line hemodiafilter; white bars, RST machine connected to circuit; SCUF, slow continuous ultrafiltration; CVVH, continuous veno-venous hemofiltration; CVVHD, continuous venovenous hemodialysis; CVVHDF, continuous veno-venous hemodiafiltration; ECMO, extracorporeal membrane oxygenation; RST, renal support therapy.